News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute lymphocytic leukemia (ALL)] News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Novartis AG (NVS)’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing     12/6/2016
As Rival Juno (JUNO) Falters, Kite Pharma (KITE) Touts New CAR-T Data and Maps Out BLA Submission Plans     12/5/2016
FDA Clears Expanded Use of Amgen (AMGN)'s Blincyto     9/2/2016
Juno (JUNO) Halts CAR-T Cancer Trial After Three Patient Deaths     7/11/2016
Novartis AG (NVS) Ponders Over Using a Medical Device-Like Sales Model for Experimental Cancer Therapy     5/17/2016
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR     4/25/2016
Juno (JUNO) Unveils Promising Early Data on Two CAR T Cell Product Candidates     4/21/2016
Novartis AG (NVS)’s Experimental Therapy Wipes Out Blood Cancer in 93 Percent of Patients     12/11/2015
FDA Designates Pfizer (PFE)’s Acute Lymphoblastic Leukemia Drug Breakthrough Status     10/21/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Speedy FDA Approval For Amgen (AMGN)'s Leukemia Immunotherapy BLINCYTO     12/5/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients     10/20/2014
Amgen (AMGN)'s Leukemia Drug Blinatumomab Gets FDA Priority Review     10/10/2014

News from Around the Web

Press Releases
CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At European Organization for Research and Treatment of Cancer-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium     12/2/2016
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia     12/1/2016
ERYtech Pharma Presents New Data On GRASPA’s Mechanism Of Action At American Society of Hematology Annual Meeting     12/1/2016
ERYtech Pharma Withdraws App for GRASPA After the CHMP Calls for More Data     11/15/2016
Amgen (AMGN) Release: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia     6/10/2016
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Yields High Remission Rates And Favorable Tolerability In Phase I Portion Of Phase I/II Clinical Trial For AML     6/10/2016
Cantargia Receives Notice Of Allowance From USPTO On IL1RAP In Acute Lymphatic Leukemia     6/8/2016
ASCO2016: Juno (JUNO)’s Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates In Adults With B-Cell ALL     6/6/2016
FDA Grants Priority Review For Amgen (AMGN)'s Supplemental Biologics License Application For Blincyto (Blinatumomab)     5/4/2016
Celator Pharma (CPXX) To Report First Quarter 2016 Financial Results On May 10, 2016     5/4/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial     4/19/2016
Juno (JUNO) Announces Data Presentations At The AACR Annual Meeting     4/14/2016
Amgen (AMGN) Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab)     3/2/2016
Xencor To Host Fourth Quarter And Full Year 2015 Financial Results Webcast And Conference Call On March 7, 2016     2/29/2016
ERYtech Pharma Announces 2016 Financial Calendar     2/8/2016

//-->